Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801340 | 0.84 | POLB (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL18134700 | 0.84 | POLB (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL22277150 | 0.82 | ACKR3 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5ALDH1A1 | |
| SCHEMBL26184790 | 0.82 | CHRNB2 (0.39) | CHRNB2CHRNA7CHRNA4CHRNA5ALDH1A1 | |
| SCHEMBL336170 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL336171 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL18378505 | 0.80 | ALDH1A1 (0.40) | CHRNB2CHRNA7CHRNA4CHRNA5ALDH1A1 | |
| SCHEMBL18925122 | 0.80 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL12847892 | 0.79 | ACKR3 (0.44) | ALDH1A1CYP1A2 | |
| SCHEMBL18502527 | 0.79 | MAPT (0.43) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093382-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| WO-2011073155-A1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110087022-A1 | Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | disclosed |
| US-7872124-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7595334-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-09-29 | — | — | US | disclosed |
| US-7244752-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-17 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087022-A1 | Dipeptidyl Peptidase Inhibitors | DPP4, DPP3, DPP9 | CHRNB2 3487/4885CHRNA7 3635/4885CHRNA4 1884/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | CHRNB2 769/4885CHRNA7 1129/4885CHRNA4 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.